The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | MANIFEST study of pelabresib (CPI-0610) in myelofibrosis
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, presents the results of the phase 2 MANIFEST study of pelabresib (CPI-0610), an oral BET inhibitor, as a monotherapy or in addition to ruxolitinib, in refractory or intolerant advanced myelofibrosis. Preliminary data indicate that pelabresib alone or as an add-on is generally well-tolerated and provides clinical benefits, and the study is being further expanded. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
